Sa Sativa

Charlotte's Web


Overview:

Charlotte's Web is a sativa that has gotten popular, mostly because it has astonishing medicinal uses. With less than half of a percent of THC (0.3% on average), Charlotte's Web is the perfect strain to treat seizures. It has high levels of CBDs, meaning it does not get the user incredibly buzzed or “high”, like many strains do, but it will treat ailments such as epilepsy. The first patient that was given the Colorado-grown strain was named Charlotte and it is said that the trichomes create a sort of “web”, giving the strain its namesake. The strain smells strongly of pine and other heavy woods. It is known to grow long, narrow leaves, just like most sativas, whilst sporting sticky trichomes. Being used primarily for pain, epilepsy, and even anxiety. The problem with Charlotte's Web for some is that it has very few psychoactive effects. While this is useful if you do not like your medicinal herb to affect your inhibitions, it can be a negative. Although Charlotte's Web is known to treat pain, its effects are so hard to pinpoint that it sometimes, it will not help cure pain at all. It is dependent on body chemistry and preference. The most common complaints regarding the strain include headaches and dizziness. Because of the bizarre headband with which it leaves the user, it can be lead to severe migraine. Use with caution, for this is a unique strain that may affect you differently than any other cannabis strain you have had before.

Strain Attributes:

Effects

Focused

Giggly

Happy

Relaxed

Uplifted

Focused

Giggly

Happy

Relaxed

Uplifted

Medical Uses

Negatives

Anxious

Dizzy

Dry Eyes

Dry Mouth

Headache

Anxious

Dizzy

Dry Eyes

Dry Mouth

Headache


Rate this Strain!

SPONSORS


FROM OUR BLOG


Medical

Cannabis Prevents Diabetes in Overweight People Says New Study

The researchers sought out to understand the connection between fasting insulin levels, insulin resistance, and cannabis consumption in a sample of more than 129,000 adults. They found that obese people who had a history of cannabis use, and those who use it currently, had significant changes in their insulin levels compared to non-cannabis users.
Opinion

Dr. Raphael Mechoulam Discovers More Potent Lab-Created Cannabinoids Than Natural Cannabis Plants

A few months ago, the father of marijuana research, Professor Raphael Mechoulam, unveiled his newest discovery: the cannabidiolic acid (EPM 301). His introduction of the latest, patented substance caused much excitement in the marijuana industry, especially within the medical cannabis sector.  His compound is entirely stable, synthetic, and an acid-based cannabinoid molecule. It was announced to the world in collaboration with EPM, a global biotechnology company in America. EPM seeks to bridge the gap between the pharmaceutical industry and the cannabis market. 
Medical

New THC-CBD Pill for MS and Huntington's Disease May Be First to Benefit from Biden's New Marijuana Research Bill

In related news, President Biden signed the Marijuana Research and Expansion Act into law. This will speed up researchers' bids for DEA schedule 1 registration authorization to undertake these trials. After seven hard years of waiting, the MMJ group of firms can finish their mission of performing clinical studies on Huntington's Disease and Multiple Sclerosis. MMJ has received FDA Orphan Designation for its Huntington's disease clinical trials.